Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H. Kalunian KC, et al. Among authors: morand ef. Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11. Arthritis Rheumatol. 2023. PMID: 36369793 Free PMC article. Clinical Trial.
Body composition in systemic lupus erythematosus.
Kipen Y, Strauss BJ, Morand EF. Kipen Y, et al. Among authors: morand ef. Br J Rheumatol. 1998 May;37(5):514-9. doi: 10.1093/rheumatology/37.5.514. Br J Rheumatol. 1998. PMID: 9651078
Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg.
Morand EF, Trasieva T, Berglind A, Illei G, Tummala R. Morand EF, et al. Ann Rheum Dis. 2019 Nov;78(11):e122. doi: 10.1136/annrheumdis-2018-214487. Epub 2018 Oct 29. Ann Rheum Dis. 2019. PMID: 30373881 No abstract available.
285 results